Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Breast cancer treatments: updates and new challenges
A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
A Basu, G Ramamoorthi, G Albert, C Gallen… - Frontiers in …, 2021 - frontiersin.org
Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …
in the tumor which are critical for activation of anti-tumor response either directly by …
Targeted therapy and mechanisms of drug resistance in breast cancer
Simple Summary Internationally, in women, breast cancer (BC) is the most common cancer
type and is the leading cause of cancer-related death. There are two main histological …
type and is the leading cause of cancer-related death. There are two main histological …
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy
Z Xu, X Han, D Ou, T Liu, Z Li, G Jiang, J Liu… - Applied microbiology …, 2020 - Springer
Autophagy is a highly conserved catabolic process and participates in a variety of cellular
biological activities. The phosphoinositide 3-kinase (PI3K)/protein kinase B …
biological activities. The phosphoinositide 3-kinase (PI3K)/protein kinase B …
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
J Wang, B Xu - Signal transduction and targeted therapy, 2019 - nature.com
Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …
Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer
C Dong, J Wu, Y Chen, J Nie, C Chen - Frontiers in pharmacology, 2021 - frontiersin.org
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
[HTML][HTML] Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
C Marchiò, L Annaratone, A Marques, L Casorzo… - Seminars in cancer …, 2021 - Elsevier
The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic
factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of …
factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of …
SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
J Luo, H Zou, Y Guo, T Tong, L Ye, C Zhu, L Deng… - Breast Cancer …, 2022 - Springer
Breast cancer (BC) has been ranked the most common malignant tumor throughout the
world and is also a leading cause of cancer-related deaths among women. SRC family …
world and is also a leading cause of cancer-related deaths among women. SRC family …
[HTML][HTML] The exciting new field of HER2-low breast cancer treatment
D Eiger, E Agostinetto, R Saúde-Conde… - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer can express, at varied levels, a protein named HER2,
commonly responsible for making it grow and send distant metastases. In the past, patients …
commonly responsible for making it grow and send distant metastases. In the past, patients …
Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials
AE Maennling, MK Tur, M Niebert, T Klockenbring… - Cancers, 2019 - mdpi.com
The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine
kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted …
kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted …